Are you saying NW wouldnt be farther along if someone more experienced in the biotech arena where not running the Company? Why have they not submitted to the US or EU? Why is Flaskworks not further along? Why has there not been a partnership deal that would climate the need of constant dilution to the common? Why did it take 4 years after data-lock to submit a MAA in a small market such as the UK? Why is there no plan for uplisting? Why has no movement happned with submiting a BLA in the US or EU (where the real $ is). Why do they continue to enrich themselves with more options when the common shareholder is down 80-90%? Why does NW continue to tell their story on the Big Biz Show vs. a actual Investor Conference sponsored by WS Investors? Why haven't they submitted the cost analysis to NICE so can NICE can make a judgement upon UK approval? They have fumbled and bumbled their way through this process, but people still give them a pass. When in reality they should be well ahead of where they are now. In biotech, no technology stops so you can implement yours. There is a very good chance DCVax may be superseded by something better the longer this goes on.
Market Data 
Markets 
AI
